GLMD Financials

Income Statement
MetricQ2 2020Q2 2019Q4 2015Q4 2014
Revenue
Cost of Revenue
0
0
0
0
Gross Profit
Operating Expenses
5.8M
+23.7%
4.7M
R&D
5.0M
+42.3%
3.5M
SG&A
845.0K
-30.0%
1.2M
Operating Income
-5816000
-23.7%
-4701000
EBITDA
-5816000
-23.7%
-4701000
0
0
Net Income
-5526000
-32.5%
-4169000
EPS (Basic)
$-374.40
-30.0%
$-288.00
EPS (Diluted)
$-374.40
-30.0%
$-288.00
Shares (Diluted)
14.7K
+0.2%
14.7K
+90.3%
7.7K
+7.5%
7.2K
Galmed Pharmaceuticals (GLMD) — Financials